RT Journal Article
SR Electronic
T1 Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 3305
DO 10.1183/13993003.congress-2022.3305
VO 60
IS suppl 66
A1 S Burkill
A1 C M. Porsbjerg
A1 A Bourdin
A1 T N Tran
A1 N Martin
A1 R Katial
A1 P Barker
A1 M E Wechsler
A1 J Maspero
A1 S Bosnic-Anticevich
A1 L P Chung
A1 G Katsoulotos
A1 G C Christoff
A1 T A Popov
A1 M Sadatsafavi
A1 C A Torres-Duque
A1 C Ulrik
A1 K Dahl Assing
A1 S Hansen
A1 A Altraja
A1 L A Lehtimaki
A1 N G Papadopoulos
A1 K Kostikas
A1 S Salvi
A1 R W Costello
A1 P Francesca
A1 T Iwanaga
A1 C K Rhee
A1 M Al-Ahmad
A1 D Larenas-Linnemann
A1 J A Fonseca
A1 R Amaral
A1 K Alving
A1 R Al-Lehebi
A1 L Perez De-Llano
A1 B Kirenga
A1 M Tsai
A1 B Mahboub
A1 P E Pfeffer
A1 W Henley
A1 Y Liu
A1 J Lyu
A1 C Goh
A1 T Uthaman
A1 D Price
A1 J Townend
YR 2022
UL http://erj.ersjournals.com/content/60/suppl_66/3305.abstract
AB Introduction/Background: Biologics (Bx) are known to decrease specific biomarker levels: anti-IL5 reduces blood eosinophils (BEC) and anti-IgE slightly reduces FeNO. Anti-IL5 and anti-IgE are thought to have limited effect on total IgE (IgE).Aims and Objectives: To assess the proportions of severe asthma patients whose biomarkers (BEC, FeNO, and serum IgE) decrease following anti-IL5 and anti-IgE initiation.Methods: Patients in the International Severe Asthma Registry (ISAR) with biomarker and Bx data were included. From pre-Bx baseline to the post-Bx time period, the median (IQR) change in biomarker level and the proportion of patients with >25% decrease in biomarkers were determined.Results: At 2-3 years from Bx initiation, BEC decreased by >25% in 80.7% of anti-IL5 and 41.6% of anti-IgE patients. FeNO decreased by >25% in 41.6% of anti-IL5 and 47.8% of anti-IgE patients. IgE decreased by >25% in 41.7% of anti-IL5 and 15.6% of anti-IgE patients (Figure).Figure: Median (IQR) biomarker changes and patient proportions with decreased biomarkers in response to Bx.Conclusions: Anti-IL5 was superior in decreasing BEC and both Bx classes decreased FeNO to a limited extent. The lower proportion of anti-IgE patients with IgE reduction could be attributed to serum total IgE (not free IgE) measurement. Apart from anti-IL5’s effect on BEC, <50% patients had decreased biomarkers; the clinical implications should be explored.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 3305.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).